Study aid only. Verify against current guidelines before clinical use.
Board-Prep Notes

Disease-site reference notes for boards review.

Platelet Disorders

Benign Hematology
Platelet Disorders

Platelet biology (granules and function)

  • Normal hemostatic sequence:
    • Adhesion: platelet binds subendothelial vWF and collagen via GPIb-IX-V (vWF) and GPVI (collagen).
    • Activation: shape change exposes GPIIb/IIIa receptors; granule release.
    • Aggregation: cross-linking of activated GPIIb/IIIa by fibrinogen (and vWF) bridges platelets.
    • Propagation of coagulation: activated platelets provide an anionic phospholipid surface for assembly of procoagulant enzyme complexes.
Platelet granules
GranuleContentsNotes
Alpha granulesvWF, fibrinogen, PF4, PDGF, TGF-β1, Factor V, P-selectin
  • PF4 binds and neutralizes heparin-like molecules (inhibits local antithrombin, enhances coagulation)
  • P-selectin mediates platelet-leukocyte (via PSGL-1) and endothelial adhesion of leukocytes and sickle RBCs and stabilizes platelet aggregates; inhibited by crizanlizumab (used in SCD)
  • Deficient in gray platelet syndrome
Dense (delta) granulesADP/ATP, serotonin, calcium
  • ADP activates and recruits additional platelets; serotonin is a vasoconstrictor; calcium is required for fibrinogen binding to GPIIb/IIIa
  • Deficient in storage pool disease, Hermansky-Pudlak, Chediak-Higashi

Diagnostic approach

  • Platelet count + smear: first step, rule out pseudothrombocytopenia. Assess platelet size and granularity, review RBC morphology (schistocytes) and WBC morphology (infection, MYH9 inclusions, blasts). MPV normal ~7 to 10 fL; large platelets are nearly as big as an RBC.
  • Bleeding history (ISTH-BAT): mucocutaneous pattern (like vWD), epistaxis, gingival bleeding, menorrhagia, postoperative and post-dental bleeding.
Platelet size on the smear
Smear findingDisorders
Microthrombocytopenia (small)Wiskott-Aldrich syndrome; X-linked thrombocytopenia
Macrothrombocytopenia (large/giant)MYH9-related disorders; Bernard-Soulier syndrome (B = Big); high platelet turnover
Poor granularityGray platelet syndrome (↓ granules)

Testing for platelet disorders

Four-tier testing pathway for a suspected platelet disorder: count, smear and bleeding history; PFA-100 screen; LTA, flow cytometry and electron microscopy; then genetic panel testing, with VerifyNow and TEG platelet mapping marked as not diagnostic.
Stepwise laboratory testing for a suspected inherited platelet disorder. Tap to enlarge.
  • Electron microscopy: identifies dense granule deficiencies, Hermansky-Pudlak, delta storage pool disorders, Chediak-Higashi.
  • PFA-100: whole blood exposed to a membrane coated with collagen/epinephrine (Col/Epi) or collagen/ADP (Col/ADP); platelet plug closes the aperture (closure time). Useful screen; low sensitivity for primary secretion defects and storage pool disease; does NOT differentiate platelet disorders from vWD; affected by anemia/hematocrit.
  • Light transmission aggregometry (LTA): gold standard for platelet aggregation, uses platelet-rich plasma (aggregates → less turbidity → increased light transmission).
    • LTA limitations: not reliable at platelet count <150,000/mm³; affected by platelet size; requires large sample and standardization; mild defects hard to interpret.
    • Whole blood aggregometry: measures change in electrical impedance; more physiologic, less manipulation.
    • VerifyNow: turbidimetric test using ADP or arachidonic acid to measure inhibition from ASA or P2Y12 blockers.
  • Flow cytometry: fluorescently labeled antibodies detect glycoprotein and activation-pathway defects. Small sample, uses whole blood, not dependent on platelet count, detects more specific and mild defects. Surface GPIb/IX (Bernard-Soulier), GPIIb/IIIa (Glanzmann), Intracellular WASp in leukocytes (Wiskott-Aldrich), Ia/IIa (collagen receptor defects). After agonist exposure: CD62p (P-selectin) for alpha granule release, CD63 for dense granule release. Also used for anti-platelet drug testing and transfusion medicine.
  • Thromboelastography (TEG) and platelet mapping: platelet mapping is a TEG modification measuring platelet aggregation to ADP or arachidonic acid, reported as percent inhibition. Designed for monitoring antiplatelet therapy, NOT diagnostic for inherited platelet disorders; may help peri-operatively.
  • Genetic testing: high-throughput sequencing for single-nucleotide variants (separate testing for copy-number/gross rearrangements). British Society of Haematology: offer genetic analysis to all patients suspected of a hereditary platelet disorder; an HTS panel should include all ISTH-listed causative genes; counsel on variants of uncertain significance and incidental findings. May be avoidable if other tests confirm the diagnosis; impacts family planning and management.
Flow cytometry: platelet activation markers
Activation eventMarker(s)Other names
Fibrinogen receptorPAC-1, LIBS/RIBS, fluorescent fibrinogen, anti-fibrinogen antibodiesGPIIb/IIIa, CD41/61
Collagen receptorAntibody detecting conformational changeGPIa/IIa, CD49b/CD29
Alpha granule exocytosisP-selectin, CD40L, thrombospondin, multimerinP-selectin = CD62p/​GMP140/​PADGEM; CD40L = CD154; GMP-33 = N-terminal thrombospondin fragment
Dense granule exocytosisMepacrine staining, CD63, LAMP-2CD63 = LIMP/​granulophysin; CD107b = LAMP-2

Aggregometry: agonists and patterns

Decision flow for reading light transmission aggregometry: absent ristocetin agglutination corrected by normal plasma means vWD and not corrected means Bernard-Soulier; absent aggregation to all other agonists means Glanzmann; selective patterns indicate aspirin or COX defect, P2Y12 defect, storage pool disease or GPVI deficiency.
Reading LTA patterns step by step: ristocetin first, then the other agonists. Tap to enlarge.
  • Agonists and behavior:
    • Epinephrine: most unreliable of all agonists.
    • ADP: biphasic response (second wave ↓ by P2Y12 inhibitors).
    • Collagen: strongest agonist used in testing.
    • Ristocetin: causes GPIb/vWF-dependent platelet agglutination (not true aggregation).
    • Arachidonic acid: converted to thromboxane A2 by COX; AA wave is ↓↓↓ with ASA (COX inhibited).
Light transmission aggregometry patterns
Disorder / exposureRistocetinADP / epi / collagenKey point
Bernard-SoulierAbsentNormalAbsent ristocetin NOT corrected by normal plasma (GPIb defect); agglutination abnormal, aggregation normal.
vWDAbsent / reducedNormalRistocetin defect CORRECTS with normal plasma (vWF added), unlike Bernard-Soulier.
Glanzmann thrombastheniaNormal agglutinationAbsentAbsent aggregation to ALL agonists except ristocetin (GPIIb/IIIa defect); impaired clot retraction.
Storage pool / Hermansky-PudlakNormalReduced / absent second waveLack of dense granules → loss of ADP second wave.
Aspirin / COX or AA defectNormalAbsent arachidonic acid response; blunted second waveCOX blocked → no thromboxane A2 generation.
P2Y12 defect / inhibitorNormalReduced ADP response (loss of second wave)P2RY12 defect or clopidogrel/prasugrel/ticagrelor.

Inherited qualitative platelet disorders

Chart pairing clinical clues such as albinism, eczema with immunodeficiency, hearing loss with nephritis, myelofibrosis with high B12, severe infections, familial AML or bleeding delayed 12 to 24 hours after a procedure with the inherited platelet disorder, gene and inheritance each one suggests.
Clues beyond the platelet count that name the inherited platelet disorder, with gene and inheritance. Tap to enlarge.
  • Glanzmann thrombasthenia: ITGA2B/ITGB3 (GPIIb/IIIa) defect → absent fibrinogen-mediated aggregation. Autosomal recessive (no bleeding in heterozygotes). Severe mucocutaneous bleeding from infancy; normal platelet count and size. GT is second in the alphabet → defect in GPIIb/IIIa. Diagnosed younger than Bernard-Soulier. LTA: absent aggregation to ALL agonists EXCEPT ristocetin; impaired clot retraction; normal PT/PTT/TT (afibrinogenemia gives identical aggregation but abnormal TT). Dx by flow cytometry (decreased GPIIb/IIIa in classic GT; variant GT may express near-normal but dysfunctional receptor), confirmed with aggregometry, clot retraction, and ITGA2B/ITGB3 testing. Frequent platelet transfusions → alloimmunization → pregnant patients can have infants with neonatal alloimmune thrombocytopenia. Tx: rFVIIa (NovoSeven) for acute bleeding, antifibrinolytics, HLA-matched platelets if alloimmunized.
  • Bernard-Soulier syndrome: GP1BA, GP1BB, GP9 defect (GPIb-IX-V, the vWF receptor) → no vWF binding, no adhesion. Autosomal recessive (little family history). Second-most diagnosed inherited platelet disorder in adults; commonly misdiagnosed as chronic ITP. Macrothrombocytopenia with giant platelets (usually platelets >30K, not extremely low); older patients than Glanzmann. B = Big, GP1B, binds von Willebrand factor (ristocetin-enhanced). Absent ristocetin agglutination NOT corrected by normal plasma (vs vWD which corrects); normal ADP/epi/collagen. Tx similar to Glanzmann.
  • GPVI deficiency: congenital or acquired defect of the platelet collagen receptor. Rare; absent aggregation to collagen (even high concentration). Inherited GP6 deficiency: isolated collagen-response defect, usually mild bleeding, normal count. Acquired (anti-GPVI autoantibodies, often with ITP or autoimmune disease): may have mild thrombocytopenia and more variable (mild-to-severe) bleeding.
  • LAD-III (leukocyte adhesion deficiency III): rare AR syndrome from defective integrin activation (FERMT3/kindlin-3). Affects leukocytes and platelets → severe bacterial infections + bleeding (Glanzmann-like defect with intact integrin expression). Tx: HSCT. A RASGRP2 variant (CalDAG-GEFI deficiency) causes abnormal GPIIb/IIIa signaling and a Glanzmann-like defect.
  • Wiskott-Aldrich syndrome (WAS): X-linked, WAS gene (WASP, an actin-cytoskeleton reorganization protein). Triad plus: thrombocytopenia + small platelets + eczema + immunodeficiency, plus autoimmunity and increased lymphoma/malignancy. Loss-of-function → classic WAS and X-linked thrombocytopenia; gain-of-function → X-linked neutropenia. Tx: supportive (prophylactic antimicrobials, platelet transfusion, IVIG); allo-HSCT is curative; autologous gene therapy (etuvetidigene autotemcel, Waskyra) FDA approved December 2025 for patients 6 months and older without a suitable HLA-matched related donor. X-linked thrombocytopenia (XLT) is a milder variant (congenital microthrombocytopenia, mild eczema, near-normal life expectancy).
  • MYH9-related disorders (formerly May-Hegglin, Sebastian, Fechtner, Epstein): autosomal dominant (~30% de novo), MYH9 encodes nonmuscle myosin IIA → weak cytoskeleton contraction, reduced clot stability. Macrothrombocytopenia + Dohle-body-like leukocyte inclusions. Variable: sensorineural hearing loss, nephritis/renal failure, cataracts. Bleeding usually mild to moderate (platelet function nearly normal).
  • Hermansky-Pudlak syndrome: HPS1, 3, 4, 5, 6 and others (all AR). Dense-granule storage pool defect → loss of the ADP second wave. Oculocutaneous albinism + bleeding + granulomatous colitis + pulmonary fibrosis (HPS1, HPS4; lung transplant clue). Increased reticuloendothelial ceroid, congenital nystagmus, reduced visual acuity. Affects 1 in 1,800 in northwest Puerto Rico. Confirm with EM and nucleotide-release studies.
  • Chediak-Higashi syndrome: AR, LYST/CHS1 (BEACH-family vesicle-trafficking protein) → giant dysfunctional inclusion bodies. Partial albinism + immunodeficiency (impaired chemotaxis/phagolysosome function) + mild bleeding + neurologic defects; most progress to an accelerated (HLH-like) phase. Tx: supportive; allo-HSCT in severe cases.
  • Gray platelet syndrome (NBEAL2): absent alpha granules → washed-out (gray) platelets on light microscopy; dense granules generally preserved. Moderate thrombocytopenia, mild-to-moderate bleeding. Progressive thrombocytopenia, myelofibrosis, splenomegaly, elevated serum B12. Mostly AR (NBEAL2, chromosome 3p21); an AD form is linked to GFI1B.
  • Griscelli syndrome: melanosome-transport disorder with partial albinism; RAB27A (type 2) causes HLH susceptibility, not a characteristic platelet dense-granule bleeding disorder.
  • Storage pool disease (delta granule): dense-granule deficiency; mild-moderate bleeding; LTA shows reduced second-wave aggregation.
  • Quebec platelet disorder: tandem duplication of PLAU → excess urokinase (uPA) in alpha granules → premature intra-platelet fibrinolysis and depletion of platelet Factor V (about 20% of total blood FV is stored in platelet alpha granules). Mild thrombocytopenia; delayed bleeding 12 to 24 h after surgery/dental work; poor wound healing; heavy menstrual bleeding. Dx: platelet FV/fibrinogen/uPA analysis, genetics. Tx: peri-procedural TXA or aminocaproic acid.
  • Platelet-type vWD: gain-of-function GP1BA (GPIb-alpha) → excessive platelet-vWF binding → thrombocytopenia and loss of HMW multimers. Abnormal RIPA (increased to low-dose ristocetin) with loss of HMW multimers; mimics type 2B vWD.
  • Familial platelet disorder with predisposition to AML: RUNX1 (AD) → thrombocytopenia/platelet dysfunction with leukemia risk. Other transcription-factor disorders: GATA1 (X-linked thrombocytopenia with dyserythropoiesis), FLI1 (Paris-Trousseau/Jacobsen), GFI1B.
  • Scott syndrome: TMEM16F (ANO6) defect → impaired platelet phospholipid scrambling (defective procoagulant surface exposure).

Functional classification of inherited platelet disorders

Schematic of two platelets forming a plug on the vessel wall with callouts mapping adhesion, aggregation, granule, signaling, cytoskeletal and procoagulant-surface steps to the inherited platelet disorders and drugs that disrupt them.
Inherited platelet disorders mapped to the step of platelet function they disrupt. Tap to enlarge.
  • Adhesion defects: vWD or platelet-type vWD; Bernard-Soulier syndrome; GPVI deficiency (collagen response).
  • Aggregation defects: Glanzmann thrombasthenia; Glanzmann-like disorders; LAD-III; congenital afibrinogenemia (no plasma fibrinogen).
  • Storage pool diseases: dense granule (Hermansky-Pudlak, Chediak-Higashi); alpha granule (gray platelet syndrome, Quebec platelet disorder, arthrogryposis-renal dysfunction-cholestasis [ARC] syndrome).
  • Cytoskeletal / structural protein defects: Wiskott-Aldrich; filamin (FLNA); (TUBB1, ACTN1, MYH9 not typically associated with major dysfunction).
  • Transcription factor abnormalities: RUNX1, GATA1, FLI1 (Paris-Trousseau), GFI1B.
  • Receptor and signaling defects: G proteins (Gaq, Gai2, Gas); effector enzymes (phospholipase C-β2, PKC-theta); receptor defects of ADP (P2Y12), thromboxane A2, GPVI, GPIa/IIa.
Inherited platelet disorders: genesGrouped by inheritance
InheritancePlatelet disorderGene(s)
ARBernard-Soulier syndrome (BSS)GP1BA; GP1BB; GP9 (all AR)
Glanzmann thrombasthenia (GT)ITGA2B; ITGB3
Bleeding due to glycoprotein VI deficiencyGP6
Hermansky-Pudlak syndromeHPS1, 3, 4, 5, 6; AP3B1; DTNBP1; BLOC1S3 (all AR)
Gray platelet syndromeNBEAL2
Chediak-Higashi syndromeLYST
Thrombocytopenia absent radius (TAR) syndromeRBM8A
ADP (P2Y12) receptor defectP2RY12
Congenital amegakaryocytic thrombocytopenia (CAMT)MPL
Phospholipase A2, group IVA deficiencyPLA2G4A
Ghosal syndromeTBXAS1
Thromboxane A2 receptor defectTBXA2R (autosomal dominant reported; biallelic defects also occur)
ADPlatelet-type von Willebrand diseaseGP1BA
Familial platelet disorder with predisposition to AMLRUNX1
May-Hegglin and other MYH9-related disordersMYH9
Paris-Trousseau thrombocytopenia and Jacobsen syndromeFLI1
Quebec platelet disorderPLAU
Amegakaryocytic thrombocytopenia with radioulnar synostosisHOXA11
Autosomal dominant thrombocytopeniaANKRD26; CYCS; TUBB1 (all AD)
Hereditary thrombocythemia (THCYT1)THPO
Dense granule abnormalitiesNBEA
X-linkedWiskott-Aldrich syndrome (WAS)WAS
X-linked thrombocytopenia with dyserythropoiesisGATA1
Filamin A-related disordersFLNA

Acquired platelet dysfunction

Four-panel map of acquired platelet dysfunction: antiplatelet and other drugs, uremia with its four defects and five fixes, causes that strip high-molecular-weight vWF multimers (MPN with platelets above 1 million, severe aortic stenosis, bypass or VAD) with their fixes, and liver disease, MDS and paraproteins.
Acquired platelet dysfunction grouped by mechanism, with the main fix where one applies. Tap to enlarge.
  • Antiplatelet drugs (most common cause): aspirin (irreversible COX-1, effect ~7 to 10 days; detectable within 1 h); clopidogrel/prasugrel/ticagrelor (P2Y12 inhibitors); GPIIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban); dipyridamole and cilostazol (PDE inhibitors); vorapaxar (PAR1); SSRIs.
  • Uremia / chronic renal disease: platelet dysfunction independent of platelet count via multiple mechanisms:
    • Adhesion defect (rationale for desmopressin benefit).
    • Decreased secretion: impaired arachidonic acid/prostaglandin metabolism, altered endothelial NO and PGI2.
    • Storage pool defect: reduced dense-granule ADP and serotonin (platelet activation during dialysis); TXA2 generation is impaired separately via the COX pathway.
    • GPIIb/IIIa signaling defect: impaired fibrinogen binding (circulating guanidinosuccinate / Arg-Gly-Asp peptides).
    • Management: dialysis (HD or PD, most effective); DDAVP (↑ vWF, shortens bleeding time in 50 to 75%); cryoprecipitate; raise hematocrit with RBC transfusion and EPO; conjugated estrogens (IV or oral, slower onset, longer-lasting). Transfused platelets acquire the same defect, so more may be needed.
  • Liver disease: thrombocytopenia (76% mild-moderate in cirrhosis, 13% severe <50K) plus dysfunction (↓ TXA2 synthesis, storage pool deficiency, GPIb defect), anemia contribution; also 10 to 20% portal vein thrombosis and embolic risk. Lusutrombopag and avatrombopag can raise platelets before a procedure (e.g., TIPS).
  • Bone marrow disease: MPN, MDS (abnormal aggregation to several agonists, especially collagen; granule defects), leukemias, dysproteinemias.
  • MPN (ET, PV): extreme thrombocytosis >1M → acquired vWF syndrome (excess platelet mass adsorbs and clears HMW vWF multimers) → paradoxical bleeding; cytoreduce.
  • Multiple myeloma / dysproteinemia: paraprotein coats platelets → dysfunction.
  • Cardiopulmonary bypass / VAD: platelet activation and granule loss → acquired storage pool deficiency; acquired loss of HMW vWF multimers; increased thrombosis risk; transient post-op dysfunction.
  • Severe aortic stenosis (Heyde syndrome): shear-induced loss of HMW vWF multimers + GI angiodysplasia bleeding; resolves after aortic valve replacement.
  • Medications (non-antiplatelet): NSAIDs (reversible COX inhibition; do not combine with aspirin); high-dose penicillins (nafcillin) and cephalosporins (moxalactam, cefotaxime), nitrofurantoin; cardiovascular drugs (beta-blockers, nitrates, verapamil, quinidine, statins, dextrans); psychotropics (SSRIs, TCAs, phenothiazines); anesthetics; chemotherapy (mithramycin, BCNU, daunorubicin, MEK/tyrosine kinase/JAK inhibitors, ibrutinib [BTK]); radiographic contrast; dietary (vitamin E, fish oil, garlic, ginger, turmeric, ethanol).

High yield

  • Glanzmann: GPIIb/IIIa defect; LTA fails ALL agonists except ristocetin; normal count/size; younger than BSS.
  • Bernard-Soulier: GPIb defect; macrothrombocytopenia with giant platelets; absent ristocetin NOT corrected by normal plasma (vs vWD which corrects).
  • vWD vs BSS on aggregometry: add normal plasma; vWD corrects, BSS does not.
  • Wiskott-Aldrich: X-linked thrombocytopenia + small platelets + eczema + immunodeficiency.
  • Hermansky-Pudlak: albinism + bleeding + pulmonary fibrosis (HPS1/4); loss of ADP second wave.
  • Gray platelet syndrome: absent alpha granules; myelofibrosis, splenomegaly, high B12.
  • MYH9-related: macrothrombocytopenia + Dohle-like leukocyte inclusions, plus/minus nephritis/deafness/cataracts.
  • Quebec platelet disorder: PLAU duplication, delayed bleeding, treat with antifibrinolytics.
  • Aspirin irreversibly inhibits COX-1; effect lasts ~7 to 10 days; arachidonic acid wave absent.
  • Uremia: dialyze, DDAVP, cryoprecipitate, conjugated estrogens, raise hematocrit.
  • AVWS in MPN with platelets >1M: cytoreduce.
  • Platelet mapping / VerifyNow: monitor antiplatelet therapy, NOT for diagnosing inherited disorders.
Veli Bakalov MD, Board Review Notes 2026

For patients

Plain-language guides on Step by Step, the free patient site from HemeOncBuddy.

Medicine guides for patients: Heparin, Daunorubicin, Ibrutinib